These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24016166)

  • 1. Cost analyses approaches in medical education: there are no simple solutions.
    Walsh K; Levin H; Jaye P; Gazzard J
    Med Educ; 2013 Oct; 47(10):962-8. PubMed ID: 24016166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis in medical education: definition of essential terms.
    Walsh K
    Med Teach; 2014 Oct; 36(10):890-3. PubMed ID: 25072235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Benefits, costs and analysis in diagnostic radiology: definitions and glossary].
    Golder W
    Rofo; 1999 Jan; 170(1):73-9. PubMed ID: 10071648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of hospice care.
    Robinson BE; Pham H
    Clin Geriatr Med; 1996 May; 12(2):417-28. PubMed ID: 8799358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation for ophthalmologists.
    Kuper H; Jofre-Bonet M; Gilbert C
    Ophthalmic Epidemiol; 2006 Dec; 13(6):393-401. PubMed ID: 17169853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision support tools to optimize economic outcomes for type 2 diabetes.
    Shaya FT; Chirikov VV
    Am J Manag Care; 2011 Nov; 17 Suppl 14():S377-83. PubMed ID: 22214425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal.
    Beale SJ; Bending MW; Trueman P; Naidoo B
    Eur J Public Health; 2012 Dec; 22(6):869-73. PubMed ID: 23132876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMEE Guide No. 123 - How to read studies of educational costs.
    Maloney S; Cook DA; Golub R; Foo J; Cleland J; Rivers G; Tolsgaard MG; Evans D; Abdalla ME; Walsh K
    Med Teach; 2019 May; 41(5):497-504. PubMed ID: 30794756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis in oncology.
    Evans WK
    Praxis (Bern 1994); 2000 Mar; 89(12):492-6. PubMed ID: 10771589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A social cost-benefit criterion for evaluating Voluntary Counseling and Testing with an application to Tanzania.
    Brent RJ
    Health Econ; 2010 Feb; 19(2):154-72. PubMed ID: 19266590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-inclusive evaluation: a banquet of approaches for including costs, benefits, and cost-effectiveness and cost-benefit analyses in your next evaluation.
    Yates BT
    Eval Program Plann; 2009 Feb; 32(1):52-4. PubMed ID: 18977532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.